[Field Notes] Bipolar & Schizophrenia Data, Generalized Anxiety Meds, and the Validity of the DSM
Mental health news for the week of June 11th, 2026
Welcome back to Field Notes!
Last week we covered the June psychiatry journals, the buprenorphine-plus-ketamine trial, and the DT-120 phase 2b update. This week is a shorter one — the post-conference dust is settling after the American Society of Clinical Psychopharmacology meeting, and a long-running argument about whether psychiatric diagnoses are “real” got a fresh airing.
A first-of-its-kind at-home treatment for bipolar and schizophrenia moves toward FDA decision
BioXcel Therapeutics presented new phase 3 analyses from its SERENITY At-Home trial for acute agitation in bipolar disorder and schizophrenia, but currently only in medically supervised settings. The trial enrolled 246 patients with a history of agitation episodes despite stable treatment, and tracked more than 1,100 self-administered episodes over 12 weeks. (Psychiatric Times)
The exploratory analysis reported the drug reduced agitation versus placebo across mild, moderate, and severe baseline episodes, with the largest effect in severe episodes, and the benefit held with repeat dosing. The FDA has set an action date of November 14, 2026 on the label-expansion application. If approved, it would be the first FDA-cleared treatment for acute agitation that patients can use at home rather than in a clinic or hospital. (BioXcel / GlobeNewswire)
The validity and the future of the DSM
Psychiatric Times ran a piece this month on where the DSM is heading — specifically the push to add biomarkers and contextual factors to future editions, and the unresolved question underneath it all: whether the diagnostic categories psychiatry uses actually carve nature at its joints, or are useful-but-imperfect labels. The authors lay out the critics’ case for an evidence-based overhaul against the practical reality that clinicians need shared categories to work and get paid. (Psychiatric Times)
Generalized anxiety medications?
Generalized anxiety disorder is seeing more drug-development activity than it has in nearly two decades — no new pharmacologic agent had been approved for GAD in over 19 years as of the most recent count. The next few months of trial readouts will say a lot about whether that changes. (Psychiatric Times)
Pride Month: a clinical-coverage note
Psychiatric Times has built its June editorial theme around mental health care for LGBTQ+ and other minoritized patients — social determinants, research, and practice guidance for clinicians. Not a single study so much as a useful body of clinically-oriented reading, given how consistently the research ties minority stress and discrimination to elevated rates of anxiety, depression, and PTSD. (Psychiatric Times)
The reading pile
What My Bones Know: A Memoir of Healing from Complex Trauma by Stephanie Foo. A re-recommend rather than a new release — Foo has supplied a couple of this series’ closing quotes, and her account of living with C-PTSD remains one of the clearest first-person windows into the diagnostic-categories debate above: what it’s actually like to be the person the labels are arguing over.
That’s the week. Back next Thursday with another round.
‘Til next week, take good care of yourself.
